270 related articles for article (PubMed ID: 23894442)
1. Cost effectiveness of cryptococcal antigen screening as a strategy to prevent HIV-associated cryptococcal meningitis in South Africa.
Jarvis JN; Harrison TS; Lawn SD; Meintjes G; Wood R; Cleary S
PLoS One; 2013; 8(7):e69288. PubMed ID: 23894442
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of CRAG-LFA screening for cryptococcal meningitis among people living with HIV in Uganda.
Ramachandran A; Manabe Y; Rajasingham R; Shah M
BMC Infect Dis; 2017 Mar; 17(1):225. PubMed ID: 28335769
[TBL] [Abstract][Full Text] [Related]
3. The cost-effectiveness of prophylaxis strategies for individuals with advanced HIV starting treatment in Africa.
Walker SM; Cox E; Revill P; Musiime V; Bwakura-Dangarembizi M; Mallewa J; Cheruiyot P; Maitland K; Ford N; Gibb DM; Walker AS; Soares M;
J Int AIDS Soc; 2020 Mar; 23(3):e25469. PubMed ID: 32219991
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of a national cryptococcal antigen screening program for HIV-infected patients in Uganda: A cost-effectiveness modeling analysis.
Rajasingham R; Meya DB; Greene GS; Jordan A; Nakawuka M; Chiller TM; Boulware DR; Larson BA
PLoS One; 2019; 14(1):e0210105. PubMed ID: 30629619
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of cryptococcal antigenemia and cost-effectiveness of a cryptococcal antigen screening program--Vietnam.
Smith RM; Nguyen TA; Ha HT; Thang PH; Thuy C; Lien TX; Bui HT; Le TH; Struminger B; McConnell MS; Fanfair RN; Park BJ; Harris JR
PLoS One; 2013; 8(4):e62213. PubMed ID: 23626792
[TBL] [Abstract][Full Text] [Related]
6. Cryptococcal Antigen Screening in Patients Initiating ART in South Africa: A Prospective Cohort Study.
Longley N; Jarvis JN; Meintjes G; Boulle A; Cross A; Kelly N; Govender NP; Bekker LG; Wood R; Harrison TS
Clin Infect Dis; 2016 Mar; 62(5):581-587. PubMed ID: 26565007
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of screening and treatment of cryptococcal antigenaemia among HIV-infected persons in Soweto, South Africa.
Govender NP; Roy M; Mendes JF; Zulu TG; Chiller TM; Karstaedt AS
HIV Med; 2015 Sep; 16(8):468-76. PubMed ID: 25689352
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4+ cell count < or = 100 cells/microL who start HIV therapy in resource-limited settings.
Meya DB; Manabe YC; Castelnuovo B; Cook BA; Elbireer AM; Kambugu A; Kamya MR; Bohjanen PR; Boulware DR
Clin Infect Dis; 2010 Aug; 51(4):448-55. PubMed ID: 20597693
[TBL] [Abstract][Full Text] [Related]
9. Cryptococcal antigenemia is associated with meningitis or death in HIV-infected adults with CD4 100-200 cells/mm
Wykowski J; Galagan SR; Govere S; Wallis CL; Moosa MY; Celum C; Drain PK
BMC Infect Dis; 2020 Jan; 20(1):61. PubMed ID: 31959112
[TBL] [Abstract][Full Text] [Related]
10. Laboratory-Reflex Cryptococcal Antigen Screening Is Associated With a Survival Benefit in Tanzania.
Faini D; Kalinjuma AV; Katende A; Mbwaji G; Mnzava D; Nyuri A; Glass TR; Furrer H; Hatz C; Boulware DR; Letang E
J Acquir Immune Defic Syndr; 2019 Feb; 80(2):205-213. PubMed ID: 30422904
[TBL] [Abstract][Full Text] [Related]
11. Prospective cohort of AIDS patients screened for cryptococcal antigenaemia, pre-emptively treated and followed in Brazil.
Borges MASB; de Araújo Filho JA; Oliveira BJS; Moreira IS; de Paula VV; de Bastos AL; Soares RBA; Turchi MD
PLoS One; 2019; 14(7):e0219928. PubMed ID: 31344140
[TBL] [Abstract][Full Text] [Related]
12. Screening HIV-Infected Patients with Low CD4 Counts for Cryptococcal Antigenemia prior to Initiation of Antiretroviral Therapy: Cost Effectiveness of Alternative Screening Strategies in South Africa.
Larson BA; Rockers PC; Bonawitz R; Sriruttan C; Glencross DK; Cassim N; Coetzee LM; Greene GS; Chiller TM; Vallabhaneni S; Long L; van Rensburg C; Govender NP
PLoS One; 2016; 11(7):e0158986. PubMed ID: 27390864
[TBL] [Abstract][Full Text] [Related]
13. Cryptococcal antigen screening and early antifungal treatment to prevent cryptococcal meningitis: a review of the literature.
Kaplan JE; Vallabhaneni S; Smith RM; Chideya-Chihota S; Chehab J; Park B
J Acquir Immune Defic Syndr; 2015 Apr; 68 Suppl 3():S331-9. PubMed ID: 25768872
[TBL] [Abstract][Full Text] [Related]
14. Cryptococcal-related Mortality Despite Fluconazole Preemptive Treatment in a Cryptococcal Antigen Screen-and-Treat Program.
Wake RM; Govender NP; Omar T; Nel C; Mazanderani AH; Karat AS; Ismail NA; Tiemessen CT; Jarvis JN; Harrison TS
Clin Infect Dis; 2020 Apr; 70(8):1683-1690. PubMed ID: 31179488
[TBL] [Abstract][Full Text] [Related]
15. Cryptococcal antigen prevalence in HIV-infected Tanzanians: a cross-sectional study and evaluation of a point-of-care lateral flow assay.
Rugemalila J; Maro VP; Kapanda G; Ndaro AJ; Jarvis JN
Trop Med Int Health; 2013 Sep; 18(9):1075-1079. PubMed ID: 23937699
[TBL] [Abstract][Full Text] [Related]
16. Establishing a cost-per-result of laboratory-based, reflex Cryptococcal antigenaemia screening (CrAg) in HIV+ patients with CD4 counts less than 100 cells/μl using a Lateral Flow Assay (LFA) at a typical busy CD4 laboratory in South Africa.
Cassim N; Schnippel K; Coetzee LM; Glencross DK
PLoS One; 2017; 12(2):e0171675. PubMed ID: 28166254
[TBL] [Abstract][Full Text] [Related]
17. Integrating cryptococcal antigen screening and pre-emptive treatment into routine HIV care.
Rajasingham R; Meya DB; Boulware DR
J Acquir Immune Defic Syndr; 2012 Apr; 59(5):e85-91. PubMed ID: 22410867
[TBL] [Abstract][Full Text] [Related]
18. Implementation and Operational Research: Evaluation of a Public-Sector, Provider-Initiated Cryptococcal Antigen Screening and Treatment Program, Western Cape, South Africa.
Vallabhaneni S; Longley N; Smith M; Smith R; Osler M; Kelly N; Cross A; Boulle A; Meintjes G; Govender NP
J Acquir Immune Defic Syndr; 2016 Jun; 72(2):e37-e42. PubMed ID: 26926942
[TBL] [Abstract][Full Text] [Related]
19. Prevalence and mortality of cryptococcal disease in adults with advanced HIV in an urban tertiary hospital in Sierra Leone: a prospective study.
Lakoh S; Rickman H; Sesay M; Kenneh S; Burke R; Baldeh M; Jiba DF; Tejan YS; Boyle S; Koroma C; Deen GF; Beynon F
BMC Infect Dis; 2020 Feb; 20(1):141. PubMed ID: 32059703
[TBL] [Abstract][Full Text] [Related]
20. Estimating the cost-per-result of a national reflexed Cryptococcal antigenaemia screening program: Forecasting the impact of potential HIV guideline changes and treatment goals.
Cassim N; Coetzee LM; Schnippel K; Glencross DK
PLoS One; 2017; 12(8):e0182154. PubMed ID: 28829788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
